Top Markets
Coin of the day
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc.

CNSP
Rang in Aktien #33273
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily... CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Aktienkurs
$5.47
Zuletzt synchronisiert: 2026-08-14
Marktkapitalisierung
$7.99M
Veränderung (1 Tag)
6.21%
Veränderung (1 Jahr)
7.47%
Land
US
Handel CNS Pharmaceuticals, Inc. (CNSP)

Kategorie

Kursverlauf für CNS Pharmaceuticals, Inc. (CNSP)
Höchster Schlusskurs: $5.27 am 2026-08-01

Niedrigster Schlusskurs: $3.79M am 2019-11-01
Kursverlauf der Aktie von CNS Pharmaceuticals, Inc. von 2019 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -16.52%
2025 -89.84%
2024 -99.87%
2023 -34.43%
2022 -90.86%
2021 -58.90%
2020 -43.49%
2019 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$505.24 28.63%
US
$846.09 29.41%
NL
$737.68 7.34%
CH
$1.07K -6.40%
KR
$254.55 12.96%
BE